Clinical Trial Results: A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating CRLX101 (NLG207) with weekly paclitaxel in recurrent/persistent epithelial ovarian, Fallopian tube, or primary peritoneal cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CRLX101
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-06-18